Inflammatory cytokines and mortality in a cohort of HIV-infected adults with alcohol problems

AIDS

Volumn 28, Issue 7, 2014, Pages 1059-1064

  Fuster, Daniel ^a   Cheng, Debbie M ^a,b   Quinn, Emily K ^c   Armah, Kaku A ^d   Saitz, Richard ^a,b   Freiberg, Matthew S ^e   Samet, Jeffrey H ^a,c   Tsui, Judith I ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Biostatistics ^*  (United States)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

alcohol; cytokines; HIV; interleukin 6; mortality

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYSTATIN C; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; SERUM AMYLOID A; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALCOHOLISM; ARTICLE; COCAINE DEPENDENCE; COHORT ANALYSIS; DISEASE ASSOCIATION; FEMALE; HEROIN DEPENDENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; BLOOD; COMPLICATION; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; SURVIVAL ANALYSIS;

ADULT; ALCOHOLISM; BIOMARKERS; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; SURVIVAL ANALYSIS;

EID: 84897512522     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000184     Document Type: Article

References (70)

1. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sorensen HT, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007; 146:87-95.
2. Obel N, Omland LH, Kronborg G, Larsen CS, Pedersen C, Pedersen G, et al. Impact of non-HIV and HIV risk factors on survival in HIV-infected patients on HAART: a population-based nationwide cohort study. PLoS One 2011; 6:e22698.
3. Hoffmann CJ, Fielding KL, Johnston V, Charalambous S, Innes C, Moore RD, et al. Changing predictors of mortality over time from cART start: implications for care. J Acquir Immune Defic Syndr 2011; 58:269-276.
4. Nijhawan AE, Clark C, Kaplan R, Moore B, Halm EA, Amarasingham R. An electronic medical record-based model to predict 30-day risk of readmission and death among HIV-infected inpatients. J Acquir Immune Defic Syndr 2012; 61:349-358.
5. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.
6. Tien PC, Choi AI, Zolopa AR, Benson C, Tracy R, Scherzer R, et al. Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr 2010; 55:316-322.
7. Armah KA, McGinnis K, Baker J, Gibert C, Butt AA, Bryant KJ, et al. HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation. Clin Infect Dis 2012; 55:126-136.
8. Eastburn A, Scherzer R, Zolopa AR, Benson C, Tracy R, Do T, et al. Association of low level viremia with inflammation and mortality in HIV-infected adults. PLoS One 2011; 6:e26320.
9. Wolf K, Tsakiris DA, Weber R, Erb P, Battegay M, Swiss HIV Cohort Study. Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis 2002; 185:456-462.
10. Justice AC, Freiberg MS, Tracy R, Kuller L, Tate JP, Goetz MB, et al. Does an index composed of clinical data reflect effects of inflammation, coagulation, and monocyte activation on mortality among those aging with HIV? Clin Infect Dis 2012; 54:984-994.
11. Choi A, Scherzer R, Bacchetti P, Tien PC, Saag MS, Gibert CL, et al. Cystatin C, albuminuria, and 5-year all-cause mortality in HIV-infected persons. Am J Kidney Dis 2010; 56:872-882.
12. Macias J, Leal M, Delgado J, Pineda JA, Munoz J, Relimpio F, et al. Usefulness of route of transmission, absolute CD8RT-cell counts, and levels of serum tumor necrosis factor alpha as predictors of survival of HIV-1-infected patients with very low CD4R T-cell counts. Eur J Clin Microbiol Infect Dis 2001; 20:253-259.
13. Ostrowski SR, Gerstoft J, Pedersen BK, Ullum H. Impaired production of cytokines is an independent predictor of mortality in HIV-1-infected patients. AIDS 2003; 17:521-530.
14. Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, et al. Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J Infect Dis 2009; 200:973-983.
15. Martinez E, Larrousse M, Podzamczer D, Perez I, Gutierrez F, Lonca M, et al. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction. AIDS 2010; 24:F1-F9.
16. Baker JV, Neuhaus J, Duprez D, Cooper DA, Hoy J, Kuller L, et al. Inflammation predicts changes in high-density lipoprotein particles and apolipoprotein A1 following initiation of antiretroviral therapy. AIDS 2011; 25:2133-2142.
17. Kim AY, Chung RT. Coinfection with HIV-1 and HCV: a onetwo punch. Gastroenterology 2009; 137:795-814.
18. Samet JH, Cheng DM, Libman H, Nunes DP, Alperen JK, Saitz R. Alcohol consumption and HIV disease progression. J Acquir Immune Defic Syndr 2007; 46:194-199.
19. Samet JH, Horton NJ, Meli S, Freedberg KA, Palepu A. Alcohol consumption and antiretroviral adherence among HIVinfected persons with alcohol problems. Alcohol Clin Exp Res 2004; 28:572-577.
20. Samet JH, Phillips SJ, Horton NJ, Traphagen ET, Freedberg KA. Detecting alcohol problems in HIV-infected patients: use of the CAGE questionnaire. AIDS Res Hum Retroviruses 2004; 20:151-155.
21. Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198.
22. Smith KL, Horton NJ, Saitz R, Samet JH. The use of the minimental state examination in recruitment for substance abuse research studies. Drug Alcohol Depend 2006; 82:231-237.
23. Jacobson Brown PM, Neuman MG. Immunopathogenesis of hepatitis C viral infection: Th1/Th2 responses and the role of cytokines. Clin Biochem 2001; 34:167-171.
24. Neuman MG, Sha K, Esguerra R, Zakhari S, Winkler RE, Hilzenrat N, et al. Inflammation and repair in viral hepatitis C. Dig Dis Sci 2008; 53:1468-1487.
25. Szabo G, Aloman C, Polyak SJ, Weinman SA, Wands J, Zakhari S. Hepatitis C infection and alcohol use: a dangerous mix for the liver and antiviral immunity. Alcohol Clin Exp Res 2006; 30:709-719.
26. Castellano-Higuera A, Gonzalez-Reimers E, Aleman-Valls MR, Abreu-Gonzalez P, Santolaria-Fernandez F, De La Vega-Prieto MJ, et al. Cytokines and lipid peroxidation in alcoholics with chronic hepatitis C virus infection. Alcohol Alcohol 2008; 43:137-142.
27. Cohen HJ, Harris T, Pieper CF. Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly. Am J Med 2003; 114:180-187.
28. Boulware DR, Hullsiek KH, Puronen CE, Rupert A, Baker JV, French MA, et al. Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis 2011; 203:1637-1646.
29. Armah KA, Quinn EK, Cheng DM, Tracy RP, Baker JV, Samet JH, et al. Human immunodeficiency virus, hepatitis C, and inflammatory biomarkers in individuals with alcohol problems: a cross-sectional study. BMC Infect Dis 2013; 13:399.
30. Sobell LC, Brown J, Leo GI, Sobell MB. The reliability of the Alcohol Timeline Followback when administered by telephone and by computer. Drug Alcohol Depend 1996; 42:49-54.
31. Fuster D, Cheng DM, Quinn EK, Nunes D, Saitz R, Samet JH, et al. Chronic hepatitis C virus infection is associated with allcause and liver-related mortality in a cohort of HIV-infected patients with alcohol problems. Addiction 2014; 109:62-70.
32. Andrade BB, Hullsiek KH, Boulware DR, Rupert A, French MA, Ruxrungtham K, et al. Biomarkers of inflammation and coagulation are associated with mortality and hepatitis flares in persons coinfected with HIV and hepatitis viruses. J Infect Dis 2013; 207:1379-1388.
33. Branch AD, Van Natta ML, Vachon ML, Dieterich DT, Meinert CL, Jabs DA, et al. Mortality in hepatitis C virus-infected patients with a diagnosis of AIDS in the era of combination antiretroviral therapy. Clin Infect Dis 2012; 55:137-144.
34. Berenguer J, Alejos B, Hernando V, Viciana P, Salavert M, Santos I, et al. Trends in mortality according to hepatitis C virus serostatus in the era of combination antiretroviral therapy. AIDS 2012; 26:2241-2246.
35. Walley AY, Cheng DM, Libman H, Nunes D, Horsburgh CR Jr, Saitz R, et al. Recent drug use, homelessness and increased short-term mortality in HIV-infected persons with alcohol problems. AIDS 2008; 22:415-420.
36. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sorensen HT, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007; 146:87-95.
37. Obel N, Omland LH, Kronborg G, Larsen CS, Pedersen C, Pedersen G, et al. Impact of non-HIV and HIV risk factors on survival in HIV-infected patients on HAART: a population-based nationwide cohort study. PLoS One 2011; 6:e22698.
38. Hoffmann CJ, Fielding KL, Johnston V, Charalambous S, Innes C, Moore RD, et al. Changing predictors of mortality over time from cART start: implications for care. J Acquir Immune Defic Syndr 2011; 58:269-276.
39. Nijhawan AE, Clark C, Kaplan R, Moore B, Halm EA, Amarasingham R. An electronic medical record-based model to predict 30-day risk of readmission and death among HIV-infected inpatients. J Acquir Immune Defic Syndr 2012; 61:349-358.
40. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.
41. Tien PC, Choi AI, Zolopa AR, Benson C, Tracy R, Scherzer R, et al. Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr 2010; 55:316-322.
42. Armah KA, McGinnis K, Baker J, Gibert C, Butt AA, Bryant KJ, et al. HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation. Clin Infect Dis 2012; 55:126-136.
43. Eastburn A, Scherzer R, Zolopa AR, Benson C, Tracy R, Do T, et al. Association of low level viremia with inflammation and mortality in HIV-infected adults. PLoS One 2011; 6:e26320.
44. Wolf K, Tsakiris DA, Weber R, Erb P, Battegay M, Swiss HIV Cohort Study. Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis 2002; 185:456-462.
45. Justice AC, Freiberg MS, Tracy R, Kuller L, Tate JP, Goetz MB, et al. Does an index composed of clinical data reflect effects of inflammation, coagulation, and monocyte activation on mortality among those aging with HIV? Clin Infect Dis 2012; 54:984-994.
46. Choi A, Scherzer R, Bacchetti P, Tien PC, Saag MS, Gibert CL, et al. Cystatin C, albuminuria, and 5-year all-cause mortality in HIV-infected persons. Am J Kidney Dis 2010; 56:872-882.
47. Macias J, Leal M, Delgado J, Pineda JA, Munoz J, Relimpio F, et al. Usefulness of route of transmission, absolute CD8RT-cell counts, and levels of serum tumor necrosis factor alpha as predictors of survival of HIV-1-infected patients with very low CD4R T-cell counts. Eur J Clin Microbiol Infect Dis 2001; 20:253-259.
48. Ostrowski SR, Gerstoft J, Pedersen BK, Ullum H. Impaired production of cytokines is an independent predictor of mortality in HIV-1-infected patients. AIDS 2003; 17:521-530.
49. Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, et al. Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J Infect Dis 2009; 200:973-983.
50. Martinez E, Larrousse M, Podzamczer D, Perez I, Gutierrez F, Lonca M, et al. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction. AIDS 2010; 24:F1-F9.
51. Baker JV, Neuhaus J, Duprez D, Cooper DA, Hoy J, Kuller L, et al. Inflammation predicts changes in high-density lipoprotein particles and apolipoprotein A1 following initiation of antiretroviral therapy. AIDS 2011; 25:2133-2142.
52. Kim AY, Chung RT. Coinfection with HIV-1 and HCV: a onetwo punch. Gastroenterology 2009; 137:795-814.
53. Samet JH, Cheng DM, Libman H, Nunes DP, Alperen JK, Saitz R. Alcohol consumption and HIV disease progression. J Acquir Immune Defic Syndr 2007; 46:194-199.
54. Samet JH, Horton NJ, Meli S, Freedberg KA, Palepu A. Alcohol consumption and antiretroviral adherence among HIVinfected persons with alcohol problems. Alcohol Clin Exp Res 2004; 28:572-577.
55. Samet JH, Phillips SJ, Horton NJ, Traphagen ET, Freedberg KA. Detecting alcohol problems in HIV-infected patients: use of the CAGE questionnaire. AIDS Res Hum Retroviruses 2004; 20:151-155.
56. Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198.
57. Smith KL, Horton NJ, Saitz R, Samet JH. The use of the minimental state examination in recruitment for substance abuse research studies. Drug Alcohol Depend 2006; 82:231-237.
58. Jacobson Brown PM, Neuman MG. Immunopathogenesis of hepatitis C viral infection: Th1/Th2 responses and the role of cytokines. Clin Biochem 2001; 34:167-171.
59. Neuman MG, Sha K, Esguerra R, Zakhari S, Winkler RE, Hilzenrat N, et al. Inflammation and repair in viral hepatitis C. Dig Dis Sci 2008; 53:1468-1487.
60. Szabo G, Aloman C, Polyak SJ, Weinman SA, Wands J, Zakhari S. Hepatitis C infection and alcohol use: a dangerous mix for the liver and antiviral immunity. Alcohol Clin Exp Res 2006; 30:709-719.
61. Castellano-Higuera A, Gonzalez-Reimers E, Aleman-Valls MR, Abreu-Gonzalez P, Santolaria-Fernandez F, De La Vega-Prieto MJ, et al. Cytokines and lipid peroxidation in alcoholics with chronic hepatitis C virus infection. Alcohol Alcohol 2008; 43:137-142.
62. Cohen HJ, Harris T, Pieper CF. Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly. Am J Med 2003; 114:180-187.
63. Boulware DR, Hullsiek KH, Puronen CE, Rupert A, Baker JV, French MA, et al. Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis 2011; 203:1637-1646.
64. Armah KA, Quinn EK, Cheng DM, Tracy RP, Baker JV, Samet JH, et al. Human immunodeficiency virus, hepatitis C, and inflammatory biomarkers in individuals with alcohol problems: a cross-sectional study. BMC Infect Dis 2013; 13:399.
65. Sobell LC, Brown J, Leo GI, Sobell MB. The reliability of the Alcohol Timeline Followback when administered by telephone and by computer. Drug Alcohol Depend 1996; 42:49-54.
66. Fuster D, Cheng DM, Quinn EK, Nunes D, Saitz R, Samet JH, et al. Chronic hepatitis C virus infection is associated with allcause and liver-related mortality in a cohort of HIV-infected patients with alcohol problems. Addiction 2014; 109:62-70.
67. Andrade BB, Hullsiek KH, Boulware DR, Rupert A, French MA, Ruxrungtham K, et al. Biomarkers of inflammation and coagulation are associated with mortality and hepatitis flares in persons coinfected with HIV and hepatitis viruses. J Infect Dis 2013; 207:1379-1388.
68. Branch AD, Van Natta ML, Vachon ML, Dieterich DT, Meinert CL, Jabs DA, et al. Mortality in hepatitis C virus-infected patients with a diagnosis of AIDS in the era of combination antiretroviral therapy. Clin Infect Dis 2012; 55:137-144.
69. Berenguer J, Alejos B, Hernando V, Viciana P, Salavert M, Santos I, et al. Trends in mortality according to hepatitis C virus serostatus in the era of combination antiretroviral therapy. AIDS 2012; 26:2241-2246.
70. Walley AY, Cheng DM, Libman H, Nunes D, Horsburgh CR Jr, Saitz R, et al. Recent drug use, homelessness and increased short-term mortality in HIV-infected persons with alcohol problems. AIDS 2008; 22:415-420.